17,261 trials
Influenza
Primary: Number of Participants Age 18 to 64 Years With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 8…
Gastrointestinal Endoscopy · Gastrointestinal Polypectomy
Primary: Modified Observers Assessment of Alertness/Sedation (MOAA/S) Score 2 Minutes From Beginning of Maintenance Period — 0; 0; 0; 1 Participants
Neoplasms, Prostate · Prostate Cancer After a Radical Treatment
Primary: Time to Prostate-specific Antigen (PSA) Doubling From Baseline (in Days) — 365.5; 458.0; NA; NA days — p=<0.001
Eyelash Hypotrichosis
Primary: Change From Baseline in Eyelash Length at Month 3 — 5.65; 5.68; 5.95; 0.74 millimeters (mm)
Cataract Surgery
Primary: Number of Participants With Summed Ocular Inflammation Score (SOIS) of Zero — 157; 164 Participant
Eosinophilic Esophagitis
Primary: Number of Participants With Complete Response to Dysphagia — 9; 6 participants — p=0.74
Lymphoma, Follicular
Primary: Number of Participants With Objective Response (OR) — 0; 1; 2; 0 participants
Anaplastic Large Cell Lymphoma · Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Primary: Proportion of Participants With Confirmed Response (Complete Response, Unconfirmed Complete Response, or Partial Response) During the First 6 Courses of Treatment…
Head and Neck Cancer
Primary: Patient Response — 11; 15; 6; 0 participants
Migraine Disorders · Migraine
Primary: Adjusted Mean Change From Baseline in the Number of Migraine Headache Days (MHD) During the Last 4 Weeks of Treatment Prior to Taper — -3.8; -3.6; -3.8; -3.3 Migraine…
Chronic Stable Angina
Primary: Change in Total Exercise Time — 450.39; 411.15 seconds — p=0.025
Necrotizing Enterocolitis · Intra-abdominal Infection
Primary: Efficacy Success (Alive at Efficacy Visit,Last Culture (if Obtained) From Sterile Body Fluid is Negative for Bacteria (Except Staphylococcus Species) From Start of Study…
Leukaemia, Lymphocytic, Chronic
Primary: Number of Participants (Par.) Classified as Responders and Non-responders for Objective Response as Assessed by an Independent Endpoint Review Committee (IRC) in…
Uterine Fibroids · Uterine Leiomyomata
Primary: Treatment-related Adverse Events (AE) Per Subject Resulting From HIFU Treatment of the Uterine Fibroids — 1.3 treatment-related AE/patient
Human Immunodeficiency Virus-1
Primary: Percentage of Participants With Plasma Human Immuno Deficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) Levels Less Than 50 Copies/Milliliter (mL) — 74.60; 83.60 Percentage…